Tecentriq (atezolizumab) - Roche
Stivarga (regorafenib) - Bayer
Zaltrap (ziv-aflibercept IV) - Sanofi, Regeneron
Opdivo (nivolumab) - Ono Pharma, BMS
Avastin (bevacizumab) - Roche
Cotellic (cobimetinib) - Exelixis, Roche
Lonsurf (trifluridine/tipiracil) - Servier, Otsuka
Cyramza (ramucirumab) - Eli Lilly
OncoVAX (autologous cancer vaccine) - Vaccinogen
Vectibix (panitumumab) - Amgen, Takeda
Keytruda (pembrolizumab) - Merck (MSD)
Erbitux (cetuximab) - Eli Lilly, EMD Serono
http://www.globenewswire.com/news-release/2019/06/20/1871769/0/en/Global-Colorectal-Cancer-Forecast-and-Market-2018-2036-Avastin-will-Remain-the-Leading-Targeted-Therapy.html
 
Jun 20, 2019
 
Prev Next